Research Article

Impact of Chronic Obstructive Pulmonary Disease on Long-Term Outcome in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Table 1

Baseline patient characteristics.

VariableNo COPD ()COPD () value

Clinical characteristics
Age63.9 ± 11.366.4 ± 12.4<0.0001
Male, number (%)1368 (64.3)149 (64.0)0.93
Body mass index (kg)30.1 ± 5.830.3 ± 6.80.91
Diabetes mellitus, number (%)547 (25.8)70 (30.4)0.01
Hypertension, number (%)1440 (68.8)169 (73.5)0.02
Current smoking, number (%)279 (14.8)38 (19.1)0.04
Hyperlipidemia, number (%)1459 (80.6)154 (84.6)0.37
MI, number (%)811 (38.5)99 (43.4)0.02
F/H CAD, number (%)606 (36.5)57 (34.1)0.55
EF_le40, number (%)128 (6.0)19 (8.2)0.04
CHF, number (%)190 (9.2)48 (22.02)<0.0001
Renal Failure, number (%)141 (6.6)20 (8.6)0.07
Laboratory characteristics
White blood cells, median (, )7.5 (6.1, 9.3)8.1 (6.6, 10.3)0.0002
Hemoglobin (g/dL), median (, )13 (12, 14.1)12.9 (12, 14.1)0.17
Platelet (g/l), median (, )210 (176, 250)219 (180, 260)0.20
BUN18 (14, 22)18 (14, 24)0.27
Cr (mg/dl), median (, )1.1 (1, 1.3)1.1 (1.0, 1.2)0.47
TC (mg/dl), median (, )186 (158, 220)179 (158, 214)0.13
TG (mg/dl), median (, )147 (102, 208)141 (93, 190)0.17
LDL (mg/dl), median (, )110 (85, 138)104 (82, 129)0.03
HDL, median (, )43 (36, 52)43 (37, 54)0.13
Left main disease, number (%)39 (1.8)5 (2.2)0.74
Emergent PCI263 (12)29 (13)0.87
DES549 (26)53 (22.8)0.31
Use of medications at discharge
Aspirin, number (%)1954 (93)201 (87)0.003
Clopidogrel, number (%)1053 (50)99 (43)0.04
ACEI/ARB, number (%)1014 (48)119 (51)0.34
CCBs, number (%)571 (27)88 (38)0.001
Beta-blockers, number (%)1596 (75)169 (72)0.36
Statins, number (%)1585 (75)182 (78)0.25

MI, myocardial infarction; F/H CAD, family history of coronary artery disease; BUN, blood urea nitrogen; TG, triglyceride; total cholesterol, TC; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; PCI, percutaneous coronary intervention; DES, drug eluting stent; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockers. CCBs, calcium-channel blockers.